Over 20 million people in the US are currently afflicted by rare disease. However, since the inception of the Orphan Drug Act in 1983, over 350 drugs have received approval by the FDA to combat these ailments- a significant increase from the 10 passed in the decade before. While this number is impressive, pharmaceutical companies still have a lot of ground to cover. So what is the next step in orphan drug development?
Join us at CBI’s Orphan Drug Innovation Summit to:
- Anticipate emerging regulatory policies to successfully achieve global market access
- Maximize collaboration between pharmaceutical companies, patients, government, and venture capitalists
- Explore pricing and reimbursement issues
- Capitalize on personalized medicine
Download the full conference brochure.
Click here to register.